Ping Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Ping Li has a total of 119 co-authors. Here are the top co-authors by number of shared publications:
Bo Yao
Department of Pathology, Jinan University School of Medicine, Guangzhou, China
8 shared publicationsMinghua Wang
Department of Pathology, Longgang District People’s Hospital, The Second Affiliated Hospital of The Chinese University of Hong Kong, Shenzhen, China
7 shared publicationsGendie E. Lash
Institute of Reproductive Health and Perinatology, Guangzhou Women and Children’s Medical Center, Guangzhou Medical University, Guangzhou, China
6 shared publications- Gendie E. Lash
Division of Uterine Vascular Biology, Guangdong Provincial Clinical Research Center for Child Health, Guangzhou Institute of Pediatrics, Guangzhou Women and Children’s Medical Center, Guangzhou Medical University, Guangzhou, China
5 shared publications Jing Liu
Department of Gynecology Third Affiliated Hospital of Zhengzhou University Zhengzhou China
5 shared publicationsYongqi Wu
Department of Pathology, Jinan University School of Medicine, Guangzhou, China
5 shared publications
Latest Publications
- 8 September 2026
- Published by Springer Nature in Reproductive Sciences
- Vol. 33 (11) , 2312-2322
Galaxamide Ameliorates Cisplatin-induced Uterine Injury via Anti‑inflammatory and Antiapoptotic Mechanisms in Mice
- 8 September 2026
- Published by Springer Nature in Reproductive Sciences
- Vol. 33 (11) , 2312-2322
Galaxamide Ameliorates Cisplatin-induced Uterine Injury via Anti‑inflammatory and Antiapoptotic Mechanisms in Mice
- Open Access
- 5 August 2026
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 24 (1) , 1015
Targeting the IL-17C-M2 macrophage axis ameliorates fibrosis in endometriosis through MAPK/ERK signaling
Background: Endometriosis is characterized by inflammation and fibrosis, in which cytokines and cytokine-macrophage interactions serve as critical mediators. However, the specific mechanisms that initiate the fibrotic cascade in endometriosis remain poorly defined. Methods: Spatial transcriptomics (ST) and cellular interaction analyses were performed on human specimens of endometriotic lesions and normal endometrium. An endometriosis mouse model was used to evaluate the effect of IL-17 C neutralization with the MOR106 antibody on ectopic lesion growth and fibrosis. In vitro experiments were conducted to explore the role of IL-17 C in macrophage polarization and extracellular matrix (ECM) production by endometrial stromal cells (ESCs). Results: IL-17RE expression was significantly upregulated in endometriotic tissues compared with normal endometrium and correlated with endometriosis fibrosis. IL-17 C levels were markedly higher in patient-derived tissues and peritoneal fluid. In a mouse model of endometriosis, neutralization of IL-17 C with the MOR106 antibody inhibited ectopic lesion growth and alleviated fibrosis in both eutopic and ectopic endometrium. Importantly, MOR106 selectively reduced CD206 + M2 macrophage infiltration in lesions without significantly altering the M1 macrophage population, suggesting that IL-17 C primarily drives M2-like macrophage accumulation in vivo. In vitro, IL-17 C promoted macrophage polarization toward a pro-fibrotic M2-like phenotype, and these IL-17 C-induced M2 macrophages enhanced ECM production by ESCs via activation of the MAPK/ERK pathway. Conclusions: Targeting the IL-17 C/IL-17RE axis provides a promising novel therapeutic strategy for mitigating fibrosis in endometriosis.
- 5 August 2026
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 24 (1) , 1015
Open AccessTargeting the IL-17C-M2 macrophage axis ameliorates fibrosis in endometriosis through MAPK/ERK signaling
Background: Endometriosis is characterized by inflammation and fibrosis, in which cytokines and cytokine-macrophage interactions serve as critical mediators. However, the specific mechanisms that initiate the fibrotic cascade in endometriosis remain poorly defined. Methods: Spatial transcriptomics (ST) and cellular interaction analyses were performed on human specimens of endometriotic lesions and normal endometrium. An endometriosis mouse model was used to evaluate the effect of IL-17 C neutralization with the MOR106 antibody on ectopic lesion growth and fibrosis. In vitro experiments were conducted to explore the role of IL-17 C in macrophage polarization and extracellular matrix (ECM) production by endometrial stromal cells (ESCs). Results: IL-17RE expression was significantly upregulated in endometriotic tissues compared with normal endometrium and correlated with endometriosis fibrosis. IL-17 C levels were markedly higher in patient-derived tissues and peritoneal fluid. In a mouse model of endometriosis, neutralization of IL-17 C with the MOR106 antibody inhibited ectopic lesion growth and alleviated fibrosis in both eutopic and ectopic endometrium. Importantly, MOR106 selectively reduced CD206 + M2 macrophage infiltration in lesions without significantly altering the M1 macrophage population, suggesting that IL-17 C primarily drives M2-like macrophage accumulation in vivo. In vitro, IL-17 C promoted macrophage polarization toward a pro-fibrotic M2-like phenotype, and these IL-17 C-induced M2 macrophages enhanced ECM production by ESCs via activation of the MAPK/ERK pathway. Conclusions: Targeting the IL-17 C/IL-17RE axis provides a promising novel therapeutic strategy for mitigating fibrosis in endometriosis.
- 26 May 2026
- Published by Wiley in Molecular Reproduction and Development
- Vol. 93 (5) , e70111
Garcinol Inhibits the Proliferation of Endometriosis Cells by Regulating Cell Cycle Related Genes and Signaling Pathways
Endometriosis is a common gynecological disease with high recurrence rates after surgery and the lesions keep unlimited proliferative capacity. The effect of garcinol on cell proliferation has not been investigated in endometriosis. Herein, we studied the effect of garcinol on endometriosis by using the immortalized human endometriotic epithelial cell line 12Z and stromal cell line iheESCs. RTCA and EdU assays were used to assess cell proliferation. RNA‐Seq was used to discover the differential expression gene (DEG) profile and GSEA, KEGG, protein‐protein interaction network and the transcription factor interaction network were analyzed. We found that garcinol inhibited the cell proliferation and S phase DNA synthesis of 12Z and iheESCs cells. There were 548 DEGs in the transcription profiles of the two cell lines. The GSEA results showed that garcinol could inhibit the DNA replication and cell cycle pathways. Among the cell cycle related genes, p21 was increased, while cyclin B1, cyclin E1, CDK2, CDK4, Myc, p27 and E2F1 were significantly decreased after garcinol treatment. The level of cell cycle M phase marker, pH3 Ser10, was also reduced by garcinol. Garcinol could regulate the Akt/c‐Jun/ERK1/2 signaling pathways. Garcinol could regulate the protein‐protein interaction network and the transcription factor interaction network, in which garcinol increased the transcription factor ATF3 and FOSB expression. In conclusion, garcinol could inhibit the proliferation of endometriosis cells in vitro.
- 26 May 2026
- Published by Wiley in Molecular Reproduction and Development
- Vol. 93 (5) , e70111
Garcinol Inhibits the Proliferation of Endometriosis Cells by Regulating Cell Cycle Related Genes and Signaling Pathways
Endometriosis is a common gynecological disease with high recurrence rates after surgery and the lesions keep unlimited proliferative capacity. The effect of garcinol on cell proliferation has not been investigated in endometriosis. Herein, we studied the effect of garcinol on endometriosis by using the immortalized human endometriotic epithelial cell line 12Z and stromal cell line iheESCs. RTCA and EdU assays were used to assess cell proliferation. RNA‐Seq was used to discover the differential expression gene (DEG) profile and GSEA, KEGG, protein‐protein interaction network and the transcription factor interaction network were analyzed. We found that garcinol inhibited the cell proliferation and S phase DNA synthesis of 12Z and iheESCs cells. There were 548 DEGs in the transcription profiles of the two cell lines. The GSEA results showed that garcinol could inhibit the DNA replication and cell cycle pathways. Among the cell cycle related genes, p21 was increased, while cyclin B1, cyclin E1, CDK2, CDK4, Myc, p27 and E2F1 were significantly decreased after garcinol treatment. The level of cell cycle M phase marker, pH3 Ser10, was also reduced by garcinol. Garcinol could regulate the Akt/c‐Jun/ERK1/2 signaling pathways. Garcinol could regulate the protein‐protein interaction network and the transcription factor interaction network, in which garcinol increased the transcription factor ATF3 and FOSB expression. In conclusion, garcinol could inhibit the proliferation of endometriosis cells in vitro.
- Open Access
- 20 November 2025
- Published by Elsevier in Cell Reports Medicine
- Vol. 6 (12) , 102464
Therapeutic targeting of interleukin-17C signaling in carcinogenesis of endometriosis
- 20 November 2025
- Published by Elsevier in Cell Reports Medicine
- Vol. 6 (12) , 102464
Open AccessTherapeutic targeting of interleukin-17C signaling in carcinogenesis of endometriosis
- Open Access
- 12 November 2025
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 23 (1) , 1273
Metformin protects against cyclophosphamide-induced ovarian fibrosis by MIF/CD74-mediated macrophage polarization
Background: Cyclophosphamide (CTX) -induced ovarian fibrosis is involved in premature ovarian failure (POF). While metformin has demonstrated anti-fibrotic properties, the mechanism by which it regulates fibroblast activation, the primary effector cells in fibrosis, remains unclear in POF. Methods: The therapeutic effects of metformin were investigated in CTX-treated mice and further explored its interaction with macrophage-fibroblast crosstalk using an in vitro co-culture system. Results: RNA sequencing revealed that metformin suppressed the MIF/CD74 signaling pathway, which was significantly activated by CTX in ovarian tissues. In vitro, CTX increased the CD86+/CD206 + macrophage ratio via NF-κB pathway activation, indicating altered macrophage polarization. Metformin or the MIF inhibitor ISO-1 reversed this polarization imbalance, thereby attenuating fibroblast activation and extracellular matrix (ECM) production in co-culture models. Additionally, CD74 knockdown in fibroblasts downregulated ECM-related genes and inhibited MAPK/JNK signaling, whereas CD74 overexpression exacerbated the fibrotic responses. Conclusion: These findings highlight a novel mechanism by which metformin alleviates CTX-induced ovarian fibrosis by targeting the MIF/CD74 axis to reprogram macrophage-fibroblast communication, suggesting metformin as a protective adjuvant to improve ovarian health during chemotherapy.
- 12 November 2025
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 23 (1) , 1273
Open AccessMetformin protects against cyclophosphamide-induced ovarian fibrosis by MIF/CD74-mediated macrophage polarization
Background: Cyclophosphamide (CTX) -induced ovarian fibrosis is involved in premature ovarian failure (POF). While metformin has demonstrated anti-fibrotic properties, the mechanism by which it regulates fibroblast activation, the primary effector cells in fibrosis, remains unclear in POF. Methods: The therapeutic effects of metformin were investigated in CTX-treated mice and further explored its interaction with macrophage-fibroblast crosstalk using an in vitro co-culture system. Results: RNA sequencing revealed that metformin suppressed the MIF/CD74 signaling pathway, which was significantly activated by CTX in ovarian tissues. In vitro, CTX increased the CD86+/CD206 + macrophage ratio via NF-κB pathway activation, indicating altered macrophage polarization. Metformin or the MIF inhibitor ISO-1 reversed this polarization imbalance, thereby attenuating fibroblast activation and extracellular matrix (ECM) production in co-culture models. Additionally, CD74 knockdown in fibroblasts downregulated ECM-related genes and inhibited MAPK/JNK signaling, whereas CD74 overexpression exacerbated the fibrotic responses. Conclusion: These findings highlight a novel mechanism by which metformin alleviates CTX-induced ovarian fibrosis by targeting the MIF/CD74 axis to reprogram macrophage-fibroblast communication, suggesting metformin as a protective adjuvant to improve ovarian health during chemotherapy.
- 1 September 2025
- Published by Elsevier in Toxicology and Applied Pharmacology
- Vol. 504, 117541
Caulerpin suppresses tumor-associated angiogenesis and tumor growth via Hippo signaling in cervical cancer
- 1 September 2025
- Published by Elsevier in Toxicology and Applied Pharmacology
- Vol. 504, 117541
Caulerpin suppresses tumor-associated angiogenesis and tumor growth via Hippo signaling in cervical cancer
- Open Access
- 22 April 2025
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16, 1526709
Metformin in gynecological disorders: pathogenic insights and therapeutic implications
Metformin, the most widely used anti-diabetic drug, has been demonstrated to exert various effects, including antioxidant, anti-inflammatory, anti-tumor, and cardioprotective properties. Due to its affordability and low toxicity profile, metformin is increasingly used to prevent or treat a wide range of gynecological disorders, as evidenced by epidemiological studies, clinical trials, and animal and in vitro studies. Trial findings for non-cancer conditions such as endometriosis, premature ovarian failure (POF), and uterine fibroids remain controversial and insufficient. However, most current clinical trials for polycystic ovarian syndrome (PCOS) and gynecological malignancies are ongoing phase II–III trials. The pharmacological effects of metformin have been shown to target the insulin-like growth factor (IGF), AMP-activated protein kinase (AMPK), phosphatidylinositol 3-kinase (PI3K)/AKT, MAPK, NF-κB, and other signal transduction pathways, highlighting its potential in the treatment of gynecological disorders. In this review, we discuss the biological impacts of metformin and the mechanisms of action pertinent to the treatment of different gynecological disorders.
- 22 April 2025
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16, 1526709
Open AccessMetformin in gynecological disorders: pathogenic insights and therapeutic implications
Metformin, the most widely used anti-diabetic drug, has been demonstrated to exert various effects, including antioxidant, anti-inflammatory, anti-tumor, and cardioprotective properties. Due to its affordability and low toxicity profile, metformin is increasingly used to prevent or treat a wide range of gynecological disorders, as evidenced by epidemiological studies, clinical trials, and animal and in vitro studies. Trial findings for non-cancer conditions such as endometriosis, premature ovarian failure (POF), and uterine fibroids remain controversial and insufficient. However, most current clinical trials for polycystic ovarian syndrome (PCOS) and gynecological malignancies are ongoing phase II–III trials. The pharmacological effects of metformin have been shown to target the insulin-like growth factor (IGF), AMP-activated protein kinase (AMPK), phosphatidylinositol 3-kinase (PI3K)/AKT, MAPK, NF-κB, and other signal transduction pathways, highlighting its potential in the treatment of gynecological disorders. In this review, we discuss the biological impacts of metformin and the mechanisms of action pertinent to the treatment of different gynecological disorders.
- 16 November 2024
- Published by Wiley in The FASEB Journal
- Vol. 38 (22) , e70172
Oxidative stress drives endometrial fibrosis via TGF‐β1/MAPK signaling pathway in breast cancer
Breast cancer patients have high serum reactive oxygen species (ROS) levels, which exert toxicity on the ovary. However, it is still unclear whether tumor‐derived ROS play a role in endometrial development and function in breast cancer. Breast cancer patients and healthy controls were recruited and endometrial thickness was measured by transvaginal ultrasound (TVUS). Xenograft tumors of the breast cancer cell line MDA–MB–231 in a female BALB/c nude mice model were established, and the therapeutic mechanism of vitamin C (VC) was investigated on uterine pathology in vivo and the contribution of co‐culture of breast cancer cell and endometrial epithelial cell on this process was examined in vitro. Median thickness in endometria was lower in breast cancer patients and tumor‐bearing mice compared to controls. A gene signature of uteri in tumor‐bearing mice demonstrated differential expression of genes (DEGs) regulating extracellular matrix (ECM) and epithelial–mesenchymal transition (EMT), and activation of TGF‐β and MAPK signaling pathways. In addition, ROS, EMT‐ and ECM‐related protein levels were enhanced in uteri in tumor‐bearing mice, as well as in Ishikawa cells which were co‐cultured with MDA‐MB‐231 cells compared to controls. Supplementation with VC reduced endometrial damage, inhibited the EMT process and collagen deposition, and maintained better histologic architecture of uteri in tumor‐bearing mice via inactivation of the TGF‐β1/p38MAPK pathway. In women with breast cancer oxidative stress in the endometrium results in a fibrotic response as a consequence of EMT. VC could alleviate endometrial fibrosis via TGF‐β1/p38MAPK pathway and provide new predictive and therapeutic targets for fertility preservation in younger breast cancer patients.
- 16 November 2024
- Published by Wiley in The FASEB Journal
- Vol. 38 (22) , e70172
Oxidative stress drives endometrial fibrosis via TGF‐β1/MAPK signaling pathway in breast cancer
Breast cancer patients have high serum reactive oxygen species (ROS) levels, which exert toxicity on the ovary. However, it is still unclear whether tumor‐derived ROS play a role in endometrial development and function in breast cancer. Breast cancer patients and healthy controls were recruited and endometrial thickness was measured by transvaginal ultrasound (TVUS). Xenograft tumors of the breast cancer cell line MDA–MB–231 in a female BALB/c nude mice model were established, and the therapeutic mechanism of vitamin C (VC) was investigated on uterine pathology in vivo and the contribution of co‐culture of breast cancer cell and endometrial epithelial cell on this process was examined in vitro. Median thickness in endometria was lower in breast cancer patients and tumor‐bearing mice compared to controls. A gene signature of uteri in tumor‐bearing mice demonstrated differential expression of genes (DEGs) regulating extracellular matrix (ECM) and epithelial–mesenchymal transition (EMT), and activation of TGF‐β and MAPK signaling pathways. In addition, ROS, EMT‐ and ECM‐related protein levels were enhanced in uteri in tumor‐bearing mice, as well as in Ishikawa cells which were co‐cultured with MDA‐MB‐231 cells compared to controls. Supplementation with VC reduced endometrial damage, inhibited the EMT process and collagen deposition, and maintained better histologic architecture of uteri in tumor‐bearing mice via inactivation of the TGF‐β1/p38MAPK pathway. In women with breast cancer oxidative stress in the endometrium results in a fibrotic response as a consequence of EMT. VC could alleviate endometrial fibrosis via TGF‐β1/p38MAPK pathway and provide new predictive and therapeutic targets for fertility preservation in younger breast cancer patients.
- 1 November 2024
- Published by Elsevier in International Immunopharmacology
- Vol. 143 (Pt 3) , 113513
Caulerpin alleviates cyclophosphamide-induced ovarian toxicity by modulating macrophage-associated granulosa cell senescence during breast cancer chemotherapy
- 1 November 2024
- Published by Elsevier in International Immunopharmacology
- Vol. 143 (Pt 3) , 113513
Caulerpin alleviates cyclophosphamide-induced ovarian toxicity by modulating macrophage-associated granulosa cell senescence during breast cancer chemotherapy
- Open Access
- 28 August 2024
- Published by Springer Nature in BMC Cancer
- Vol. 24 (1) , 1-10
Galaxamide alleviates cisplatin-induced premature ovarian insufficiency via the PI3K signaling pathway in HeLa tumor-bearing mice
It is challenging to improve the effects of chemotherapy and reduce its adverse impact on the ovaries. Our previous study suggested that the combination of galaxamide could enhance the antitumor effect of cisplatin (CIS) in HeLa cell xenograft mice. However, their potential effects on ovarian tissues remain unknown. The Hela tumor-bearing female BALB/c mice model was established and randomly divided into three groups: control group (PBS group), CIS group (0.3 mg/kg CIS group) and galaxamide group (0.3 mg/kg CIS + 3 mg/kg galaxamide-treated group). The serum sex hormones levels, ovarian morphology, functional and molecular characterisation were determined and compared with those of the control group. The hormonal effects indicated premature ovarian insufficiency (POI) associated with CIS-induced tumor-bearing mice. CIS induces the apoptosis in primordial and developing follicles and subsequently increases follicular atresia, eventually leading to follicle loss. After cotreatment, galaxamide significantly increased anti-Mullerian hormone (AMH) and follicle-stimulating hormone receptor (FSHR) expression and prevented the CIS-induced PI3K pathway, which triggers follicle activation, apoptosis or atresia. These findings demonstrate that galaxamide could attenuate CIS-induced follicle loss by acting on the PI3K signaling pathway by stimulating AMH and/or FSHR and thus provides promising therapeutic options for patients with cervical cancer.
- 28 August 2024
- Published by Springer Nature in BMC Cancer
- Vol. 24 (1) , 1-10
Open AccessGalaxamide alleviates cisplatin-induced premature ovarian insufficiency via the PI3K signaling pathway in HeLa tumor-bearing mice
It is challenging to improve the effects of chemotherapy and reduce its adverse impact on the ovaries. Our previous study suggested that the combination of galaxamide could enhance the antitumor effect of cisplatin (CIS) in HeLa cell xenograft mice. However, their potential effects on ovarian tissues remain unknown. The Hela tumor-bearing female BALB/c mice model was established and randomly divided into three groups: control group (PBS group), CIS group (0.3 mg/kg CIS group) and galaxamide group (0.3 mg/kg CIS + 3 mg/kg galaxamide-treated group). The serum sex hormones levels, ovarian morphology, functional and molecular characterisation were determined and compared with those of the control group. The hormonal effects indicated premature ovarian insufficiency (POI) associated with CIS-induced tumor-bearing mice. CIS induces the apoptosis in primordial and developing follicles and subsequently increases follicular atresia, eventually leading to follicle loss. After cotreatment, galaxamide significantly increased anti-Mullerian hormone (AMH) and follicle-stimulating hormone receptor (FSHR) expression and prevented the CIS-induced PI3K pathway, which triggers follicle activation, apoptosis or atresia. These findings demonstrate that galaxamide could attenuate CIS-induced follicle loss by acting on the PI3K signaling pathway by stimulating AMH and/or FSHR and thus provides promising therapeutic options for patients with cervical cancer.